Finding ways to overcome treatment resistance in pancreatic cancer
Official title: Overcoming mechanisms of therapeutic resistance in pancreatic ductal adenocarcinoma
Funded at Salk Institute for Biological Studies · NIH-10883558 · Data updated 2026-11-12
This study is looking into why pancreatic cancer is hard to treat and hopes to find new ways to make treatments work better by understanding how the cancer cells interact with their environment, which could help patients get more effective therapies.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Salk Institute for Biological Studies NIH-funded |
| Lab location | 1 site (La Jolla, UNITED STATES) |
| Project start | July 6, 2023 |
| Project end | June 30, 2028 |
| Funding year | 2024 |
| Award (this year) | $2,922,916 |
| NIH project number | 5P01CA265762-02 |
| Project ID | NIH-10883558 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with pancreatic ductal adenocarcinoma who are seeking new treatment options.
✕Less likely to help
Patients with other types of cancer or those who are not diagnosed with pancreatic ductal adenocarcinoma may not benefit from this research.
What this research studies
This research focuses on understanding why pancreatic ductal adenocarcinoma (PDA) is so difficult to treat effectively. It investigates the tumor's unique environment, which limits drug delivery and promotes survival of cancer cells. By studying the interactions between tumor cells and their surroundings, the research aims to identify new strategies to enhance treatment responses and overcome resistance. Patients may benefit from insights that could lead to more effective therapies tailored to their specific cancer characteristics.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options and outcomes for patients with pancreatic cancer.
How similar studies have gone: Previous research has shown promise in targeting therapeutic resistance in other cancers, suggesting potential for success in this area as well.
Where this research is happening
-
Salk Institute for Biological Studies
La Jolla, United States Active
Researchers
- Principal investigator: Hunter, Tony R. — Salk Institute for Biological Studies
- Study coordinator: Hunter, Tony R.
Related research
Other NIH-funded projects on the same topics.
-
Fibrin-rich tumor stroma as a new driver of immune response in pancreatic cancer
This grant explores how fibrin-involved tumor surroundings in pancreatic cancer might affect immune therapy, with the goal of making treatments work better for patients.
-
TREM2+ macrophages and liver metastases in pancreatic cancer
Researchers are studying immune cells in liver metastases from pancreatic cancer to understand how they influence the cancer’s spread and more effective treatments.
-
Protein S could slow pancreatic cancer and blood clots
A potential treatment study looks at restoring a natural blood protein, Protein S, to help people with pancreatic cancer by slowing tumor growth and reducing dangerous clots.
-
In vivo B7-H3 CAR-T cells for pancreatic cancer therapy
A patient-friendly look at a new approach that aims to produce CAR-T cells directly inside the body to target pancreatic cancer.
-
Metabolic changes in pancreatic cancer when treated with crisantaspase
Aims to understand how pancreatic cancer cells adapt their metabolism when treated with crisantaspase to inform better treatment strategies for patients.
-
New combination therapy for pancreatic cancer in animals
A new therapy designed to weaken the tumor’s protective surroundings and boost treatment effects in pancreatic cancer models.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.